Ophthalmic Therapeutic Innovation
Ophthalmic Therapeutic Innovation
  • Home
  • About OTI
    • Mission
    • Vision
    • History
    • Contact Us
  • Pipelines & Partners
  • Breakthrough Discovery
  • Glaucoma
  • Team
  • Publications
  • News
  • More
    • Home
    • About OTI
      • Mission
      • Vision
      • History
      • Contact Us
    • Pipelines & Partners
    • Breakthrough Discovery
    • Glaucoma
    • Team
    • Publications
    • News
  • Home
  • About OTI
    • Mission
    • Vision
    • History
    • Contact Us
  • Pipelines & Partners
  • Breakthrough Discovery
  • Glaucoma
  • Team
  • Publications
  • News

Andrew Merken

Andrew Merken is a Shareholder in the Venture Capital and Emerging Growth Companies Group in the Boston office of Polsinelli, focusing on business and transactional matters for a wide range of clients, with a particular concentration on Seed round and Venture Capital financings, recapitalizations, mergers & acquisitions, private equity transactions, and corporate governance. He also represents entrepreneurs, start-up and growth-stage companies, and investment banks, as well as venture capital investors, private foundations, family offices, and angel investors, in formation and structuring matters, equity and compensation, business contracts and general business advice and planning.
 

He currently serves on Board of Directors for the American Cancer Society Eastern New England Area, Honorary Board of Advisors for Lappin Foundation, Council (Board of Directors) at Boston Bar Association, and Board of Directors for Derby (Tufts) Entrepreneurship Center. 


He holds a JD law degree from University of Pennsylvania Carey Law School.

Copyright © OTI 2025 -  All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept